NCT04111458View on ClinicalTrials.gov

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumors, KRAS Mutation; SOS1
Interventions
DRUG

BI 1701963

Tablet

DRUG

Trametinib

Tablet

Trial Locations (8)

28204

Levine Cancer Institute, Charlotte

37203

Sarah Cannon Research Institute-Nashville-48456, Nashville

50937

Universitätsklinikum Köln (AöR), Cologne

60590

Universitätsklinikum Frankfurt, Frankfurt am Main

77030

The University of Texas MD Anderson Cancer Center, Houston

02215

Dana-Farber Cancer Institute, Boston

3015 GD

Erasmus Medisch Centrum-ROTTERDAM-50697, Rotterdam

3584 CX

Universitair Medisch Centrum Utrecht, Utrecht

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04111458 - A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | Biotech Hunter | Biotech Hunter